Answer
Reported infusion-related reactions with intravenous isavuconazonium sulfate (Cresemba) include hypotension, dyspnoea, dizziness, paraesthesia, nausea and headache; the infusion should be stopped if these reactions occur.
Sources for this answer
- CRESEMBA 200mg Powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 22Document updated
Sources checked